Edman Degradation

Edman degradation is a chemical method of N-terminal sequencing of peptides and proteins, developed by Swedish biochemist Pehr Edman in 1950. It relies on sequential cycle-by-cycle cleavage of the N-terminal residue of a peptide without damaging the rest of the chain, allowing identification of the first 30-50 amino acids of a polypeptide sequence.

Chemical principle. Each Edman cycle comprises three steps: (1) coupling — phenylisothiocyanate (PITC, Edman reagent) reacts with the free N-terminal amine in basic medium (trimethylamine or pyridine) to form phenylthiocarbamate (PTC); (2) cleavage — anhydrous trifluoroacetic acid (TFA) induces intramolecular cyclisation with peptide nitrogen and releases the N-terminal residue as anilinothiazolinone (ATZ); (3) conversion and identification — unstable ATZ is converted to stable phenylthiohydantoin (PTH) by heating in aqueous acidic medium, then the PTH-amino acid derivative is identified by RP-HPLC (C18, ACN/TFA gradient) by comparison with the 20 PTH-amino acid standards.

Performance and limitations. Cycle yield reaches 95-98% under optimal conditions, but drops progressively with cumulative errors (lag, carry-over, oxidation), limiting useful sequencing to 30-50 cycles. Major limitations: (1) blocked N-terminus (pyroGlu, acetylation, N-formylation, myristoylation) preventing coupling; (2) problematic residues (oxidised Cys, phosphorylated Ser/Thr, Trp sensitive to acidic oxidation); (3) modest sensitivity (picomoles). Applied Biosystems 491, Shimadzu PPSQ, Phenomenex Procise automates perform ~1 cycle/hour.

Current role. Displaced for de novo sequencing by tandem mass spectrometry MS/MS (ESI/MALDI + CID/HCD/ETD collision, PEAKS, de Novo, MaxQuant software), Edman degradation remains used in pharmaceutical QC control (USP <1055>, peptide API batch validation), de novo proteolytic cleavage detection (biomarkers), and characterisation of synthetic peptides to confirm N→C orientation without ambiguity.